Clarity Pharmaceuticals Ltd
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CU6.AX | MNPR | AKTS | 0RC6.IL | ANL | AURA | |
|---|---|---|---|---|---|---|
| Market cap | 596.93M | 488.71M | 845.42M | 1.21B | 618.86M | 689.64M |
| P/E (TTM) | — | — | — | 60.5 | — | — |
| Forward P/E | -6.0 | -38.0 | -7.1 | — | -32.7 | -3.3 |
| Price/book | 3.2 | 3.7 | 1.7 | 5.7 | 2.9 | 2.2 |
| Dividend yield | — | — | — | 2.09% | — | — |
| 1-year change | −70.07% | −15.28% | −33.30% | −9.53% | +560.69% | +14.71% |
| Today | +15.94% | +4.18% | +1.74% | +1.32% | +0.31% | +6.57% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All CU6.AX news ›Clarity Pharmaceuticals completes recruitment for its CLARIFY prostate imaging trial
Record US Quarter: How Is Cyclopharm (ASX:CYC) Building on It? New Leaders, Big Test: Where Is IPH (ASX:IPH) Heading at Its AGM? The milestone is significant for a clinical-stage company whose valuation rests heavily on the success of its…
Clarity Pharmaceuticals hits target for SECuRE trial cohort
Assets related to this article Clarity Pharmaceuticals (ASX:CU6) completed recruitment for the main group of its Phase 1/2a SECuRE trial evaluating 16 patients with metastatic castration-resistant prostate cancer. The trial aims to assess…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- grafa.com1
- kalkinemedia.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.